Read More Pharma Industry News AviadoBio opens fourth ASPIRE-FTD cohort as AVB-101 regains full development rights and secures fresh backing from leading dementia foundations AviadoBio opens the fourth ASPIRE-FTD cohort, regains full AVB-101 rights from Astellas, and secures ADDF backing. Read what it means for FTD gene therapy. byVenkateshMarch 31, 2026